SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (373)4/12/2006 1:09:28 PM
From: tuck  Read Replies (1) of 447
 
From DNA's quarterly PR:

>>U.S. sales of Tarceva® (erlotinib) increased 94 percent to $93 million, from $48 million in the first quarter of 2005, its first full quarter of sales. Sequential quarter-over-quarter Tarceva sales increased 11 percent from fourth quarter 2005 sales of $84 million.<<

Merrill Lynch described this as "in line." Looks as though you could have stuck to your short a little longer. Meanwhile, it'll be interesting to see if the May 30 calls I wrote expire worthless.

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News